ArticleCardiovascular drugs and therapy2022

Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events.

John Maret-Ouda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.